Chronic treatment with dipeptidyl-peptidase 4 inhibition reduces vascular inflammation in metabolic syndrome model

RENNA NF; DIEZ E; MIATELLO RM

PLOS ONE

PUBLIC LIBRARY SCIENCE

Lugar: San Francisco; Año: 2014 vol. 9 p. 1 - 8

1932-6203

BACKGROUND: This study aims to demonstrate effect of incretin system, by DDP-IV inhibitor: vidagliptin (V), are actively involved in the activation of different molecular inflammatory as cytokines, NF-kB and VCAM-1 generating a microenvironment that allows cardiovascular remodeling in an experimental model of metabolic syndrome (MS), achieved by fructose administration to spontaneously hypertensive rats (FFHR) during 12 weeks. METHODS: Chronic treatment with (V) (10 mg/kg per day for the last 6 weeks) involved the increment in metabolic variables and systolic blood pressure. In addition, chronic V treatment reverted cardiovascular remodeling. RESULTS: V was able to reverse the expression of NF-kB and VCAM-1, and reduced the expression of pro-atherogenic cytokines as VEGF, Leptin, TNF-alpha and MCP-1 in vascular tissue in this experimental model. CONCLUTIONS: The data suggest the involvement of incretin system in the expression of inflammatory proteins at different vascular levels, allowing the creation of a microenvironment suitable for the creation, perpetuation, grown and destabilization of vascular injury.